Verteporfin
 |
This article does not cite any references or sources. (December 2011) |
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 3-[(23S,24R)-14-ethenyl-5-(3-methoxy-3-oxopropyl)-22,23-bis(methoxycarbonyl)-4,10,15,24-tetramethyl-25,26,27,28-tetraazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic acid | |
| Clinical data | |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a607060 |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | Intravenous |
| Identifiers | |
| CAS number | 129497-78-5  |
| ATC code | S01LA01 |
| PubChem | CID 5362420 |
| DrugBank | DB00460 |
| ChemSpider | 21106402 |
| UNII | 0X9PA28K43 |
| KEGG | D01162 |
| ChEBI | CHEBI:60775 |
| ChEMBL | CHEMBL1200573  |
| Chemical data | |
| Formula | C41H42N4O8 |
| Mol. mass | 718.794 g/mol |
|
|
|
|
 (what is this?) (verify) |
|
Verteporfin (trade name Visudyne), a benzoporphyrin derivative, is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.
Verteporfin is also used off-label for the treatment of central serous retinopathy.
Administration [edit]
Verteporfin is given intravenously, within 15 minutes before laser treatment.
Side effects [edit]
Most commonly, blurred vision. Also, photosensitivity; it is advised to avoid exposure to sunlight and unscreened lighting until 48 hours after the injection of verteporfin.
External links [edit]
|
||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
